

Sanofi  
Form 6-K  
March 14, 2016

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM 6-K**  
**REPORT OF FOREIGN PRIVATE ISSUER**  
**PURSUANT TO RULE 13a-16 OR 15d-16**  
**UNDER THE SECURITIES EXCHANGE ACT OF 1934**

For the month of March 2016

Commission File Number: 001-31368

**SANOFI**

(Translation of registrant's name into English)

54, rue La Boétie, 75008 Paris, FRANCE

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F       Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): \_\_\_\_\_

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): \_\_\_\_\_

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes       No

Edgar Filing: Sanofi - Form 6-K

If  Yes  marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b):  
82-\_\_\_\_\_

In March 2016, Sanofi issued the statements attached hereto as Exhibit 99.1 to 99.3 which are incorporated herein by reference.

**Exhibit List**

Exhibit No.	<u>Description</u>
Exhibit 99.1	Press release dated March 8, 2016: Sanofi Pasteur and MSD (Known as Merck in the United States and Canada) Announce Intent to End Joint Vaccines Operations in Europe, Sanofi Pasteur MSD, to Pursue Their Own Distinct Growth Strategies
Exhibit 99.2	Press release dated March 10, 2016: Sanofi Appoints Dr. Ameeet Nathwani to Executive Committee and Executive Vice President, Group Chief Medical Officer
Exhibit 99.3	Press release dated March 11, 2016: Sanofi and Regeneron Announce Topline Results of Phase 3 Monotherapy Study Demonstrating Superiority of Sarilumab vs. Adalimumab in Patients with Active Rheumatoid Arthritis

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: March 14, 2016

SANOFI

By           /S/          Alexandra Roger            
Name: Alexandra Roger  
Title: Head of Securities Law and  
Capital Markets

**Exhibit Index**

<u>Exhibit No.</u>	<u>Description</u>
Exhibit 99.1	Press release dated March 8, 2016: Sanofi Pasteur and MSD (Known as Merck in the United States and Canada) Announce Intent to End Joint Vaccines Operations in Europe, Sanofi Pasteur MSD, to Pursue Their Own Distinct Growth Strategies
Exhibit 99.2	Press release dated March 10, 2016: Sanofi Appoints Dr. Ameet Nathwani to Executive Committee and Executive Vice President, Group Chief Medical Officer
Exhibit 99.3	Press release dated March 11, 2016: Sanofi and Regeneron Announce Topline Results of Phase 3 Monotherapy Study Demonstrating Superiority of Sarilumab vs. Adalimumab in Patients with Active Rheumatoid Arthritis